AccessibilityHelpAbout Us
CanSino Biologics logo

CanSino Biologics(OTC) CASBF

Market Cap$728.78MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2020)-61%
5 Year-92%
1 Year-55%
1 Month-6%
$2.95
+0.00%
+0.00Today
CanSino Biologics last closing stock price
MetricPriceDate
Last closeUSD 2.952026-09-17
CanSino Biologics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-35.87%USD 4.602026-09-04
1 month-6.2%USD 3.152026-07-23
3 month+3.15%USD 2.862026-06-18
Year to date-37.83%USD 4.752025-12-31
1 year-55.3%USD 6.602025-09-17
3 year-3.59%USD 3.062023-09-18
5 year-91.58%USD 35.052021-09-17
Since inception-60.67%USD 7.502020-01-02

CanSino Biologics Financials at a Glance

Market Cap

$728.78MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CN¥1.23B

Net Income (TTM)

CN¥40.64M

EPS (TTM)

$0.02

P/E Ratio

126.07

Dividend

$0.00

Beta (Volatility)

-0.14 (Low)

Price

$2.95

Volume

5

Open

$3.11

Previous Close

$2.95

Daily Range

$2.95 - $3.11

52-Week Range

$2.60 - $6.99

Estimated Earnings Date

Nov 2, 2026

CASBF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About CanSino Biologics

CanSino Biologics Inc. is a biotechnology company focused on developing, manufacturing, and commercializing vaccines in China. The company is known for its innovative vaccine solutions, including those for COVID-19 and other infectious diseases.

Products and Services
  • Convidecia, a COVID-19 vaccine with inhalation delivery
  • Ad5-EBOV, an Ebola virus vaccine
  • DTcP vaccine for infants, currently in Phase I clinical trials
Growth Outlook
  • Recent quarterly revenue increased to CNY 358 million, showing strong demand
  • Expansion into new vaccine markets is underway, enhancing growth potential
  • Pipeline includes multiple vaccines in various stages, indicating future revenue streams
Financial Highlights
  • Trailing twelve months (TTM) revenue of CNY 1.2 billion, reflecting growth
  • Net income for Q2 2026 reached CNY 39.5 million, a positive trend
  • Current ratio of 4.39 indicates strong liquidity position
CanSino Biologics Inc. has established itself as a key player in the vaccine market, particularly in response to global health challenges. The company's innovative approach to vaccine development, including its inhalation delivery method for COVID-19, positions it well for future growth. Recent financial performance shows promising trends, with significant revenue increases and a solid liquidity position. The ongoing development of a diverse vaccine pipeline further enhances the company's potential for sustained growth and profitability.
AI Generated • Sep 7, 2026

Industry

Biotechnology

Sector

Health Care

Employees

1,134

CEO

Xue Feng Yu, PhD

Website

www.cansinotech.com

Headquarters

Tianjin, TI 300457, CN

CASBF Financials

Key Financial Metrics (TTM)

Gross Margin

72.43%

Operating Margin

1.02%

Net Income Margin

3.29%

Return on Equity

0.82%

Return on Capital

-1.81%

Return on Assets

0.59%

Earnings Yield

0.79%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$728.78MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

247.04M

Volume

5

Avg. Volume

60.889

Financials (TTM)

Gross Profit

CN¥879.24M

Operating Income

-CN¥56.69M

EBITDA

CN¥76.86M

Operating Cash Flow

CN¥40.27M

Capital Expenditure

-CN¥168.70M

Free Cash Flow

-CN¥128.33M

Cash & ST Invst.

CN¥1.84B

Total Debt

CN¥980.03M

CanSino Biologics Performance Analysis

CanSino Biologics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31CNY 153,644,038-77.0%
20232023-12-31CNY 49,276,079-67.9%
20242024-12-31CNY 116,180,186135.8%
20252025-12-31CNY 148,558,78927.9%
CanSino Biologics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3026.5%
Q42025-12-3119.3%
Q12026-03-31-49.0%
Q22026-06-3090.0%
CanSino Biologics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31CNY -0.55N/A
20232023-12-31CNY -0.8555.0%
20242024-12-31CNY -0.21-74.9%
20252025-12-31CNY 0.02N/A
CanSino Biologics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-301846.0%
Q42025-12-31-53.6%
Q12026-03-31-413.7%
Q22026-06-30200.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

CN¥358.07M

+46.0%

Gross Profit

CN¥243.45M

+27.8%

Gross Margin

67.99%

N/A

Market Cap

$728.78MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$642.66K

N/A

Employees

1,134

N/A

Net Income

CN¥39.54M

+2138.2%

EBITDA

CN¥60.37M

+373.8%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

CN¥1.84B

-43.2%

Total Debt

CN¥980.03M

-48.1%

Accounts Receivable

CN¥965.45M

+46.2%

Inventory

CN¥387.73M

+14.1%

Long Term Debt

CN¥909.48M

+4.1%

Short Term Debt

CN¥70.55M

-93.1%

Return on Assets

0.59%

N/A

Return on Invested Capital

0.21%

N/A

Free Cash Flow

-CN¥32.90M

+21.6%

Operating Cash Flow

-CN¥5.98M

-123.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
HTSUFHisamitsu Pharmaceutical Co., Inc.
$29.00+0.00%
CURLFCuraleaf Holdings, Inc.
$10.47+1.75%
LBTSFAlmirall, S.A.
$15.35-0.78%
APNHYAspen Pharmacare Holdings Limited
$9.64+1.26%

Trending Stocks

Symbol / CompanyPricePrice Chg
SPCXSpace Exploration Technologies
$152.71-1.36%
NVDANvidia
$222.27+1.34%
AGNCAGNC Investment Corp.
$9.87-0.40%
INTCIntel
$108.60-0.18%

Questions About CASBF

What is the current price of CanSino Biologics?

CanSino Biologics is trading at $2.95 per share.

What is the 52-week range for CanSino Biologics?

Over the past 52 weeks, CanSino Biologics has traded between $2.60 and $6.99.

How much debt does CanSino Biologics have?

As of the most recent reporting period, CanSino Biologics reported total debt of CN¥144.43M.

How much cash does CanSino Biologics have on hand?

CanSino Biologics reported CN¥172.84M in cash and cash equivalents in its most recent financial results.

What is CanSino Biologics’s dividend yield?

CanSino Biologics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services